Psilocybin for Depression: From Credibility to Feasibility, What’s Missing?
Antonio Munafò, Davide Arillotta, Guido Mannaioni, Fabrizio Schifano, Renato Bernardini, Giuseppina Cantarella
Pharmaceuticals December 31, 2022 DOI: 10.3390/ph16010068 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Depression Psilocybin |
| Keywords | Clinical trials Ethical concerns Methodological issues Magic mushroom treatment Behavioral health trials Mood disorder intervention Trial design |
| Citations | 15 |
| Key findings | Psilocybin-assisted psychotherapy may provide significant and sustained alleviation of depressive symptoms, but study limitations and ethical, legal, and methodological issues remain. |
Abstract
Psilocybin has been suggested as a promising transdiagnostic treatment strategy for a wide range of psychiatric disorders. Recent findings showed that psychedelic-assisted/”psycholitic” psychotherapy should provide significant and sustained alleviation of depressive symptoms. However, to date, there have been several study limitations (e.g., small sample sizes, blinding, limited follow-up, highly screened treatment populations) and some health/political issues, including practitioners’ experience, lack of standardized protocols, psychedelics’ legal status, ethical concerns, and potential psychological/psychopathological/medical untoward effects. The focus here is on a range of clinical and methodological issues, also aiming at outlining some possible suggestions. We are confident that newer evidence, more precise protocols, and eventual reclassification policies may allow a better understanding of the real potential of psilocybin as a transdiagnostic therapeutic molecule.